Detection of small cancer biomarkers with low molecular weight and a low concentration range has always been challenging yet urgent in many clinical applications such as diagnosing early-stage cancer,monitoring treatm...Detection of small cancer biomarkers with low molecular weight and a low concentration range has always been challenging yet urgent in many clinical applications such as diagnosing early-stage cancer,monitoring treatment and detecting relapse.Here,a highly enhanced plasmonic biosensor that can overcome this challenge is developed using atomically thin two-dimensional phase change nanomaterial.By precisely engineering the configuration with atomically thin materials,the phase singularity has been successfully achieved with a significantly enhanced lateral position shift effect.Based on our knowledge,it is the first experimental demonstration of a lateral position signal change>340μm at a sensing interface from all optical techniques.With this enhanced plasmonic effect,the detection limit has been experimentally demonstrated to be 10^(-15) mol L^(−1) for TNF-α cancer marker,which has been found in various human diseases including inflammatory diseases and different kinds of cancer.The as-reported novel integration of atomically thin Ge_(2)Sb_(2)Te_(5) with plasmonic substrate, which results in a phase singularity and thus a giant lateral position shift, enables the detection of cancer markers with low molecular weight at femtomolar level. These results will definitely hold promising potential in biomedical application and clinical diagnostics.展开更多
The specific detection of tumor markers is crucial in early tumor screening and subsequent treatment processes.To ac-curately distinguish the signal response caused by trace markers,the high demodulation resolution of...The specific detection of tumor markers is crucial in early tumor screening and subsequent treatment processes.To ac-curately distinguish the signal response caused by trace markers,the high demodulation resolution of the sensor is necessary.In this paper,we propose a dual-wavelength fiber laser sensing system enhanced with microwave photonics de-modulation technology to achieve high-resolution tumor marker detection.This sensing system can simultaneously perform spectral wavelength-domain and frequency-domain analyses.Experimental results demonstrate that this system's refractive index(RI)sensitivity reaches 1083 nm/RIU by wavelength analysis and-1902 GHz/RIU by frequency analysis,with ideal detection resolutions of 1.85×10^(-5)RIU and 5.26×10^(-8)RIU,respectively.Compared with traditional wavelength domain analysis,the demodulation resolution is improved by three orders of magnitude,based on the same sensing structure.To validate its biosensing performance,carcinoembryonic antigen-related cell adhesion molecule 5(CEACAM5)is selected as the detection target.Experimental results show that the improved sensing system has a limit of detection(LOD)of 0.076 ng/mL and a detection resolution of 0.008 ng/mL.Experimental results obtained from human serum samples are consistent with clinical data,highlighting the strong clinical application potential of the proposed sens-ing system and analysis method.展开更多
Objective:To analyze the screening effectiveness of combining the fecal occult blood test with tumor marker detection for colorectal cancer.Methods:A total of thirty patients with colorectal cancer and thirty patients...Objective:To analyze the screening effectiveness of combining the fecal occult blood test with tumor marker detection for colorectal cancer.Methods:A total of thirty patients with colorectal cancer and thirty patients with benign colon hyperplasia who received treatment from January 2020 to January 2023 were selected.These patients were assigned to the observation group and the control group,respectively.All patients in both groups underwent both fecal occult blood tests and tumor marker detection.The levels of tumor markers between the two groups were compared,the tumor marker levels in different stages were assessed within the observation group,and the positive detection rates for single detection and combined detection were compared.Results:The levels of various tumor markers in the observation group were significantly higher than those in the control group(P<0.05).Furthermore,as the Duke stage increased within the observation group,the levels of various tumor markers also increased(P<0.05).The positive detection rate of the combined test was notably higher than that of single detection(P<0.05).Conclusion:Combining the fecal occult blood test with tumor marker detection in colorectal cancer screening can significantly improve the overall detection rate.展开更多
Accurate detection of multiple small end-metabolic biomarkers is more sensitive than large biomoleculesto provide real-time feedbacks of physiological/pathologicalstate, but is more challenging due to lack of specific...Accurate detection of multiple small end-metabolic biomarkers is more sensitive than large biomoleculesto provide real-time feedbacks of physiological/pathologicalstate, but is more challenging due to lack of specific identifyinggroups. Current optical platforms suffer from unsatisfactoryresolutions to differentiate each target because they producesimilar output to different targets using a single excitation,and inevitably involve non-functional components that increase chances of interacting with non-target molecules.Herein, by taking full advantage of each building unit’sfunctionality to integrate multivariate recognition elements inone interface, a dual-excitation-driven full-component-responsive metal-organic framework (MOF)-based luminescentprobe, namely CeTMA-TMA-Eu, is successfully custom-tailored for detecting both pseudouridine (Ψ) and N-acetylaspartate (NAA), the diagnostic hallmarks of cancer andneurodegenerative disorder. Remarkably, Ψ interacts withMOF’s organic building unit (trimesic acid, TMA) and filtersout its absorptions of 262 nm-light to reduce its energytransferred to Eu^(3+), while NAA induces the valence transitionof Ce^(4+)/Ce^(3+) nodes to improve the cooperative energy transferefficacy from TMA and Ce^(3+) to Eu^(3+). As a result, this platformexhibits completely reverse photoresponses towards Ψ(“switch-off” at 262 nm excitation) and NAA (“switch-on”upon 296 nm excitation), and demonstrates excellent selectivity and sensitivity in complex biofluids, with low detection limits of 0.16 and 0.15 μM, and wide linear ranges of0–180 and 0–100 μM, respectively. Such full-componentresponsive probe with dual-excitation-mediated reverse responses for multi-small targets intrinsically minimizes its interaction with non-target molecules and amplifies resolutionto discriminate each target, providing a new strategy for improving assay accuracy of multi-small biomarkers in diagnostics.展开更多
基金We thank Shiyue Liu from School of Life Sciences in The Chinese University of Hong Kong for helpful discussions.This work is supported under the PROCORE-France/Hong Kong Joint Research Scheme(F-CUHK402/19)the Research Grants Council,Hong Kong Special Administration Region(AoE/P-02/12,14210517,14207419,N_CUHK407/16)the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie Grant Agreement No.798916.Y.Wang is supported under the Hong Kong PhD Fellowship Scheme.
文摘Detection of small cancer biomarkers with low molecular weight and a low concentration range has always been challenging yet urgent in many clinical applications such as diagnosing early-stage cancer,monitoring treatment and detecting relapse.Here,a highly enhanced plasmonic biosensor that can overcome this challenge is developed using atomically thin two-dimensional phase change nanomaterial.By precisely engineering the configuration with atomically thin materials,the phase singularity has been successfully achieved with a significantly enhanced lateral position shift effect.Based on our knowledge,it is the first experimental demonstration of a lateral position signal change>340μm at a sensing interface from all optical techniques.With this enhanced plasmonic effect,the detection limit has been experimentally demonstrated to be 10^(-15) mol L^(−1) for TNF-α cancer marker,which has been found in various human diseases including inflammatory diseases and different kinds of cancer.The as-reported novel integration of atomically thin Ge_(2)Sb_(2)Te_(5) with plasmonic substrate, which results in a phase singularity and thus a giant lateral position shift, enables the detection of cancer markers with low molecular weight at femtomolar level. These results will definitely hold promising potential in biomedical application and clinical diagnostics.
基金supported in part by the Science and Technology Department of Guangdong Province(2021A0505080002)Department of Natural Resources of Guangdong Province(GDNRC[2022]No.22)+2 种基金Science,Technology and Innovation Commission of Shenzhen Municipality(20220815121807001)Hunan Provincial Natural Science Foundation of China(under Grant Nos.2023JJ30209)Hunan Provincial Education Department Science Research Fund of China(under Grant Nos.22B0862).
文摘The specific detection of tumor markers is crucial in early tumor screening and subsequent treatment processes.To ac-curately distinguish the signal response caused by trace markers,the high demodulation resolution of the sensor is necessary.In this paper,we propose a dual-wavelength fiber laser sensing system enhanced with microwave photonics de-modulation technology to achieve high-resolution tumor marker detection.This sensing system can simultaneously perform spectral wavelength-domain and frequency-domain analyses.Experimental results demonstrate that this system's refractive index(RI)sensitivity reaches 1083 nm/RIU by wavelength analysis and-1902 GHz/RIU by frequency analysis,with ideal detection resolutions of 1.85×10^(-5)RIU and 5.26×10^(-8)RIU,respectively.Compared with traditional wavelength domain analysis,the demodulation resolution is improved by three orders of magnitude,based on the same sensing structure.To validate its biosensing performance,carcinoembryonic antigen-related cell adhesion molecule 5(CEACAM5)is selected as the detection target.Experimental results show that the improved sensing system has a limit of detection(LOD)of 0.076 ng/mL and a detection resolution of 0.008 ng/mL.Experimental results obtained from human serum samples are consistent with clinical data,highlighting the strong clinical application potential of the proposed sens-ing system and analysis method.
文摘Objective:To analyze the screening effectiveness of combining the fecal occult blood test with tumor marker detection for colorectal cancer.Methods:A total of thirty patients with colorectal cancer and thirty patients with benign colon hyperplasia who received treatment from January 2020 to January 2023 were selected.These patients were assigned to the observation group and the control group,respectively.All patients in both groups underwent both fecal occult blood tests and tumor marker detection.The levels of tumor markers between the two groups were compared,the tumor marker levels in different stages were assessed within the observation group,and the positive detection rates for single detection and combined detection were compared.Results:The levels of various tumor markers in the observation group were significantly higher than those in the control group(P<0.05).Furthermore,as the Duke stage increased within the observation group,the levels of various tumor markers also increased(P<0.05).The positive detection rate of the combined test was notably higher than that of single detection(P<0.05).Conclusion:Combining the fecal occult blood test with tumor marker detection in colorectal cancer screening can significantly improve the overall detection rate.
基金supported by the National Key Research and Development Program of China (2022YFC2403203, 2024YFF0508601)the National Natural Science Foundation of China (52172279)+3 种基金the Basic Research Program of Shanghai (21JC1406003)the Shanghai Rising-Star Program (21QA1402200)the Leading Talents in Shanghai in 2018, the Key Field Research Program (2023AB054)the Higher Education Discipline Innovation Project (B14018)。
文摘Accurate detection of multiple small end-metabolic biomarkers is more sensitive than large biomoleculesto provide real-time feedbacks of physiological/pathologicalstate, but is more challenging due to lack of specific identifyinggroups. Current optical platforms suffer from unsatisfactoryresolutions to differentiate each target because they producesimilar output to different targets using a single excitation,and inevitably involve non-functional components that increase chances of interacting with non-target molecules.Herein, by taking full advantage of each building unit’sfunctionality to integrate multivariate recognition elements inone interface, a dual-excitation-driven full-component-responsive metal-organic framework (MOF)-based luminescentprobe, namely CeTMA-TMA-Eu, is successfully custom-tailored for detecting both pseudouridine (Ψ) and N-acetylaspartate (NAA), the diagnostic hallmarks of cancer andneurodegenerative disorder. Remarkably, Ψ interacts withMOF’s organic building unit (trimesic acid, TMA) and filtersout its absorptions of 262 nm-light to reduce its energytransferred to Eu^(3+), while NAA induces the valence transitionof Ce^(4+)/Ce^(3+) nodes to improve the cooperative energy transferefficacy from TMA and Ce^(3+) to Eu^(3+). As a result, this platformexhibits completely reverse photoresponses towards Ψ(“switch-off” at 262 nm excitation) and NAA (“switch-on”upon 296 nm excitation), and demonstrates excellent selectivity and sensitivity in complex biofluids, with low detection limits of 0.16 and 0.15 μM, and wide linear ranges of0–180 and 0–100 μM, respectively. Such full-componentresponsive probe with dual-excitation-mediated reverse responses for multi-small targets intrinsically minimizes its interaction with non-target molecules and amplifies resolutionto discriminate each target, providing a new strategy for improving assay accuracy of multi-small biomarkers in diagnostics.
